Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer

Koji Hatano,Kazuo Nishimura,Yasutomo Nakai,Takahiro Yoshida,Mototaka Sato,Atsunari Kawashima,Masatoshi Mukai,Akira Nagahara,Motohide Uemura,Daizo Oka,Masashi Nakayama,Hitoshi Takayama,Kiyonori Shimizu,Norio Meguro,Tsuyoshi Tanigawa,Seiji Yamaguchi,Akira Tsujimura,Norio Nonomura

Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer

2013

Koji Hatano
Kazuo Nishimura
Yasutomo Nakai
Takahiro Yoshida
Mototaka Sato
Atsunari Kawashima
Masatoshi Mukai
Akira Nagahara
Motohide Uemura
Daizo Oka
Masashi Nakayama
Hitoshi Takayama
Kiyonori Shimizu
Norio Meguro
Tsuyoshi Tanigawa
Seiji Yamaguchi
Akira Tsujimura
Norio Nonomura

Background A low-dose chemotherapy consisting of docetaxel, estramustine and dexamethasone was investigated for its beneficial effect and feasibility in Japanese patients with metastatic castration-resistant prostate cancer (CRPC).

Keywords:

Dexamethasone
Prostate cancer
General surgery
Cancer research
Oncology
Estramustine
Castration
Internal medicine
Docetaxel
Chemotherapy
Medicine
low dose
Surgical oncology
castration resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations